February 20, 2019
Ono Pharmaceutical/Seikagaku’s novel osteoarthritis therapy ONO-5704/SI-613 met the primary endpoint in a PIII confirmatory study conducted in Japan for the treatment of knee osteoarthritis, according to topline data released by the two companies on February 19. In the PIII study,...read more